FDA Approves Durvalumab for Locally Advanced NSCLC

February 16, 2018 – The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy. The approval is based on the phase III PACIFIC trial, in which the PD-L1 inhibitor durvalumab improved median progression-free survival (PFS) by 11.2 months compared with placebo (16.8 vs 5.6 months; HR, 0.52; 95% CI, 0.42-0.65; P <.0001). The ... (leggi tutto)